Pontine Infarct as Initial Presentation of Catastrophic Antiphospholipid Syndrome in Systemic Lupus Erythematous

被引:0
作者
Rajah, Rathika [1 ]
Cader, Rizna A. [2 ]
机构
[1] Univ Kebangsaan Malaysia UKM, Dept Med, Med Ctr, Kuala Lumpur, Malaysia
[2] UKM Med Ctr, Dept Med, Nephrol Unit, Kuala Lumpur, Malaysia
关键词
Antiphospholipid Syndrome; Catastrophic APLS; Infarct; Thrombosis; Cyclophosphamide; ANTIBODIES; TIME;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Antiphospholipid syndrome (APLS) is an autoimmune condition which commonly manifests as an arterial or venous thrombosis affecting medium to large vessels, with the presence of antiphospholipid antibodies. APLS can be a primary disease by itself, or secondary to other autoimmune diseases, such as Systemic Lupus Erythematosus (SLE). Catastrophic APLS is a rare but a fatal sequelae of APLS, affecting up to three or more organs, and progresses rapidly with a high mortality rate. We report a case of catastrophic APLS in a young woman with underlying SLE who presented to us with multiple cranial nerve palsies due to bilateral pontine infarct, and eventually developed deep vein thrombosis and pulmonary embolism during the course of the illness. She was treated with high dose corticosteroids and intravenous cyclophosphamide with biochemical improvement. In this case report, we would like to highlight the fact that our patient had bilateral pontine infarcts as the initial presentation, with no inciting events and antiphospholipid antibodies were negative during the acute illness.
引用
收藏
页码:288 / 291
页数:4
相关论文
共 14 条
[1]   Catastrophic antiphospholipid syndrome: how to diagnose a rare but highly fatal disease [J].
Aguiar, Cassyanne L. ;
Erkan, Doruk .
THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE, 2013, 5 (06) :305-314
[2]   Multiorgan failure and antiphospholipid antibodies: the catastrophic antiphospholipid (Asherson's) syndrome [J].
Asherson, RA .
IMMUNOBIOLOGY, 2005, 210 (10) :727-733
[3]   Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines [J].
Asherson, RA ;
Cervera, R ;
de Groot, PG ;
Erkan, D ;
Boffa, MC ;
Piette, JC ;
Khamashta, MA ;
Shoenfeld, Y .
LUPUS, 2003, 12 (07) :530-534
[4]   Mortality in the catastrophic antiphospholipid syndrome - Causes of death and prognostic factors in a series of 250 patients [J].
Bucciarelli, Silvia ;
Espinosa, Gerard ;
Cervera, Ricard ;
Erkan, Doruk ;
Gomez-Puerta, Jose A. ;
Ramos-Casals, Manuel ;
Font, Josep ;
Asherson, Ronald A. .
ARTHRITIS AND RHEUMATISM, 2006, 54 (08) :2568-2576
[5]   Catastrophic Antiphospholipid Syndrome: Treatment, Prognosis, and the Risk of Relapse [J].
Bucciarelli, Silvia ;
Erkan, Doruk ;
Espinosa, Gerard ;
Cervera, Ricard .
CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY, 2009, 36 (2-3) :80-84
[6]   14th International Congress on Antiphospholipid Antibodies Task Force Report on Catastrophic Antiphospholipid Syndrome [J].
Cervera, Ricard ;
Rodriguez-Pinto, Ignasi ;
Colafrancesco, Serena ;
Conti, Fabrizio ;
Valesini, Guido ;
Rosario, Cristina ;
Agmon-Levin, Nancy ;
Shoenfeld, Yehuda ;
Ferrao, Claudia ;
Faria, Raquel ;
Vasconcelos, Carlos ;
Signorelli, Flavio ;
Espinosa, Gerard .
AUTOIMMUNITY REVIEWS, 2014, 13 (07) :699-707
[7]  
DRENKARD C, 1989, J RHEUMATOL, V16, P614
[8]  
Elagib EE, 2019, LUPUS, V4, P137
[9]   Antiphospholipid Syndrome and the Neurologist: From Pathogenesis to Therapy [J].
Fleetwood, Thomas ;
Cantello, Roberto ;
Comi, Cristoforo .
FRONTIERS IN NEUROLOGY, 2018, 9
[10]   Antiphospholipid syndrome: 30 years and our contribution [J].
Koike, Takao .
INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2015, 18 (02) :233-241